KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to -$10.8 million.

  • Jazz Pharmaceuticals' Cash from Financing Activities fell 10439.44% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$957.1 million, marking a year-over-year decrease of 123831.36%. This contributed to the annual value of $20.5 million for FY2024, which is 10672.1% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$10.8 million for Q3 2025, which was down 10439.44% from -$124.5 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Cash from Financing Activities registered a high of $4.7 billion during Q2 2021, and its lowest value of -$813.5 million during Q1 2025.
  • For the 5-year period, Jazz Pharmaceuticals' Cash from Financing Activities averaged around $116.2 million, with its median value being -$78.5 million (2023).
  • The largest annual percentage gain for Jazz Pharmaceuticals' Cash from Financing Activities in the last 5 years was 62588.16% (2021), contrasted with its biggest fall of 195323.53% (2021).
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Cash from Financing Activities stood at -$246.6 million in 2021, then skyrocketed by 107.95% to $19.6 million in 2022, then tumbled by 611.87% to -$100.3 million in 2023, then skyrocketed by 91.75% to -$8.3 million in 2024, then plummeted by 30.86% to -$10.8 million in 2025.
  • Its Cash from Financing Activities was -$10.8 million in Q3 2025, compared to -$124.5 million in Q2 2025 and -$813.5 million in Q1 2025.